Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIC PPI inhibitor
- Development stage
- Preclinical
- Lead developer
- Nutshell Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BIC PPI inhibitor is a small molecule therapeutic currently in the discovery stage of development by Nutshell Therapeutics for the treatment of solid tumors. The drug is designed to disrupt specific protein-protein interactions (PPI) involving the BIC protein. While the precise biology of 'BIC' is not explicitly defined in company literature, in oncology, BIC (B-cell integration cluster) typically refers to the host gene for the oncogenic microRNA miR-155, which is known to drive tumor progression, metastasis, and immune resistance. This program represents an allosteric or interface-targeting approach to modulate oncogenic signaling pathways that are otherwise difficult to target with traditional inhibitors.
- Other names
- bictegravir + proton pump inhibitorBIC protein-protein interaction inhibitor
Beyond the preview
Go deeper on BIC PPI inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIC PPI inhibitor.